Affiliation:
1. Lipidology and Center for Extracorporeal Therapy, Department of
Medicine III, University Hospital Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany
2. Division of Vascular Endothelium and Microcirculation, Department of
Medicine III, University Hospital Carl Gustav Carus, Technische
Universität Dresden, Dresden, Germany
Abstract
AbstractAn elevated cholesterol concentration has been suspected to increase the
susceptibility for SARS-COV-2 infection. Cholesterol plays a central role in the
mechanisms of the SARS-COV-2 infection. In contrast, higher HDL-cholesterol
levels seem to be protective. During COVID-19 disease, LDL-cholesterol and
HDL-cholesterol appear to be decreased. On the other hand, triglycerides (also
in different lipoprotein fractions) were elevated. Lipoprotein(a) may increase
during this disease and is most probably responsible for thromboembolic events.
This lipoprotein can induce a progression of atherosclerotic lesion formation.
The same is suspected for the SARS-COV-2 infection itself. COVID-19 patients are
at increased risk of incident cardiovascular diseases, including cerebrovascular
disorders, dysrhythmias, ischemic and non-ischemic heart disease, pericarditis,
myocarditis, heart failure, and thromboembolic disorders. An ongoing
lipid-lowering therapy, including lipoprotein apheresis, is recommended to be
continued during the COVID-19 disease, though the impact of lipid-lowering drugs
or the extracorporeal therapy on prognosis should be studied in further
investigations.
Subject
Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,General Medicine,Endocrinology, Diabetes and Metabolism
Reference47 articles.
1. Risk of acute myocardial infarction and ischaemic stroke following COVID-19 in
Sweden: a self-controlled case series and matched cohort study;I Katsoularis;Lancet,2021
2. Long-term cardiovascular outcomes of COVID-19;Y Xie;Nat Med,2022
3. Strong relationship between cholesterol, low-density lipoprotein receptor,
Na(+)/H(+) exchanger, and SARS-COV-2: this association
may be the cause of death in the patient with COVID-19;E Cure;Lipids Health Dis,2021
4. Soluble LOX-1: a novel biomarker in patients with coronary artery disease,
stroke, and acute aortic dissection?;A Hofmann;J Am Heart Assoc,2020
5. Effects of PCSK9 targeting: alleviating oxidation, inflammation, and
atherosclerosis;E Punch;J Am Heart Assoc,2022
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献